Gouni-Berthold I, Giannakidou E, Müller-Wieland D, Faust M, Kotzka J, Berthold H K, Krone W
Department of Internal Medicine II, University of Cologne and Center of Molecular Medicine Cologne (CMMC), Cologne, Germany.
J Intern Med. 2005 Mar;257(3):272-80. doi: 10.1111/j.1365-2796.2004.01446.x.
Diabetes mellitus type 2 (DM-2) is a complex disorder with a strong genetic background. Protein tyrosine phosphatase-1B (PTP-1B) dephosphorylates various receptor protein kinases in vitro, including the beta subunit of the insulin receptor, therefore representing a potential candidate to be involved in the polygenic pathogenesis of DM-2. Recently a Pro387Leu variant of the PTP-1B gene has been associated with an increased risk of DM-2 in a Danish population. Reports from China and Finland failed to confirm this association.
DESIGN, SETTING AND SUBJECTS: The purpose of the present study was to examine the possible association between the presence of DM-2 and the Pro387Leu polymorphism in a German Caucasian population. A total of 836 subjects (age 20-92 years) participated in the study. The presence of the Pro387Leu variant of the PTP-1B gene was investigated using polymerase chain reaction (PCR) restriction fragment-length polymorphism in 402 subjects with DM-2 (231 men, 171 women, age 63.1 +/- 10.8 years, BMI 28.7 +/- 5.1 kg m(-2)) and in 434 normoglycemic age- and sex-matched control subjects (248 men, 186 women, age 64.4 +/- 6.5 years, BMI 26.5 +/- 3.7 kg m(-2)).
Nine subjects in the control group and nine in the diabetic group (allelic frequency 0.99% in both groups) carried the Pro387Leu polymorphism. A meta-analysis on published data of >3000 subjects including our own data did not find an association between the polymorphism and DM-2. In addition, the polymorphism had no significant influence on the presence of atherosclerotic disease, whilst the influence of other known cardiovascular risk factors was confirmed. Furthermore, the impact of the mutation on metabolic and anthropometric parameters in both groups was examined. Amongst the controls there were no significant differences in BMI, HDL and LDL cholesterol or blood pressure between the two groups with or without the Pro387Leu polymorphism. The same was true for the diabetic group. Interestingly, in both diabetics and controls, Pro387Leu carriers had significantly higher triglycerides. In a logistic regression model only BMI and family history but not polymorphism were predictors of DM-2.
In conclusion, the present data suggest that in a German Caucasian population the Pro387Leu polymorphism of the PTP-1B gene is not associated with DM-2 but may play a role in other metabolic phenotypes.
2型糖尿病(DM-2)是一种具有强大遗传背景的复杂疾病。蛋白酪氨酸磷酸酶-1B(PTP-1B)在体外可使多种受体蛋白激酶去磷酸化,包括胰岛素受体的β亚基,因此它是参与DM-2多基因发病机制的一个潜在候选因素。最近,PTP-1B基因的Pro387Leu变异与丹麦人群中DM-2风险增加相关。来自中国和芬兰的报告未能证实这种关联。
设计、背景与研究对象:本研究的目的是在德国白种人群中检测DM-2的存在与Pro387Leu多态性之间的可能关联。共有836名受试者(年龄20 - 92岁)参与了研究。采用聚合酶链反应(PCR)限制性片段长度多态性方法,在402例DM-2患者(231名男性,171名女性,年龄63.1±10.8岁,体重指数28.7±5.1 kg/m²)和434名年龄及性别匹配的血糖正常对照者(248名男性,186名女性,年龄64.4±6.5岁,体重指数26.5±3.7 kg/m²)中检测PTP-1B基因的Pro387Leu变异。
对照组和糖尿病组各有9名受试者(两组等位基因频率均为0.99%)携带Pro387Leu多态性。对包括我们自己数据在内的3000多名受试者的已发表数据进行的荟萃分析未发现该多态性与DM-2之间存在关联。此外,该多态性对动脉粥样硬化疾病的存在没有显著影响,而其他已知心血管危险因素的影响得到了证实。此外,还研究了该突变对两组代谢和人体测量参数的影响。在对照组中,有无Pro387Leu多态性的两组之间在体重指数、高密度脂蛋白和低密度脂蛋白胆固醇或血压方面没有显著差异。糖尿病组情况相同。有趣的是,在糖尿病患者和对照组中,Pro387Leu携带者的甘油三酯水平均显著较高。在逻辑回归模型中,只有体重指数和家族史而非多态性是DM-2的预测因素。
总之,目前的数据表明,在德国白种人群中,PTP-1B基因的Pro387Leu多态性与DM-2无关,但可能在其他代谢表型中起作用。